Yahoo · Dec 31, 2025
Emmaus, NIT sign Endari distribution agreement
Under the terms of the agreement, Emmaus will receive an upfront payment and a royalty on NIT’s product sales.
EM
OTC · EMMA
Emmaus Life Sciences, Inc.
Healthcare · Biotechnology
$0.03
Up+$0.01 (+22.99%)
Updated Aug 22, 2026, 9:27 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 702.52K
- P/E ratio
- -0.1
- Dividend yield
- 0.00%
- 52-week range
- $0.01 – $0.04
- Volume
- 1.51M
- Avg. volume
- 69.57K
Price performance
EMMA price history
1M range · 15 trading sessions · Daily adjusted prices
EMMA closed at $0.03 after 15 trading sessions, up 122.51% for the selected period.
- Last close
- $0.03
- Period change
- +122.51%
- Period low
- $0.01
- Period high
- $0.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $0.0152 | $0.0384 | $0.0152 | $0.0261 | 1.51M |
| Aug 19, 2026 | $0.011 | $0.0129 | $0.011 | $0.0129 | 52.02K |
| Aug 18, 2026 | $0.0117 | $0.013 | $0.011 | $0.011 | 1.09M |
| Aug 17, 2026 | $0.0125 | $0.0125 | $0.0115 | $0.0115 | 323.2K |
| Aug 14, 2026 | $0.012 | $0.012 | $0.0115 | $0.0115 | 120.01K |
| Aug 13, 2026 | $0.012 | $0.012 | $0.011 | $0.0115 | 100K |
| Aug 12, 2026 | $0.0125 | $0.0125 | $0.0125 | $0.0125 | 100 |
| Aug 11, 2026 | $0.0135 | $0.0135 | $0.0115 | $0.0115 | 121K |
| Aug 10, 2026 | $0.0125 | $0.0125 | $0.0115 | $0.0115 | 120K |
| Aug 7, 2026 | $0.012 | $0.012 | $0.011 | $0.011 | 116.77K |
| Aug 6, 2026 | $0.01 | $0.01 | $0.01 | $0.01 | 21K |
| Aug 5, 2026 | $0.01 | $0.01 | $0.01 | $0.01 | 1K |
| Jul 29, 2026 | $0.0106 | $0.0115 | $0.01 | $0.01 | 19.13K |
| Jul 28, 2026 | $0.0118 | $0.0118 | $0.011 | $0.011 | 70K |
| Jul 27, 2026 | $0.012 | $0.012 | $0.011 | $0.0117 | 6.5K |
Latest EMMA news
The latest Smart Investors Daily articles mentioning EMMA.
Stock researchCompany · Overview
EMMA research
Overview
Company profile and research snapshot.
Company profile
EMMAUS LIFE SCIENCES INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Nov 14, 2025
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences reported a 38% decline in net revenues for Q3 2025, attributed to generic L-Glutamine competition and lower sales in the Middle East North Africa region. The company experienced a net loss of $2.1 million and reduced operating expenses by 43%.
Benzinga · Jun 26, 2025
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
Emmaus Life Sciences received FDA approval for label changes to Endari®, a sickle cell disease treatment, based on additional pharmacokinetic study data. The new labeling provides more comprehensive information about dosing and administration.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
